Evolus Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Evolus stock.
View analyst ratings for Evolus or view top-rated stocks.

Wall Street analysts have given Evolus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evolus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Evolus is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Evolus.

Evolus will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415.

Evolus, Inc. (NASDAQ:EOLS) issued its quarterly earnings data on Wednesday, May, 12th. The company reported $0.16 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.74. The firm had revenue of $12.24 million for the quarter, compared to analyst estimates of $11.42 million. Evolus had a negative trailing twelve-month return on equity of 736.81% and a negative net margin of 234.87%.
View Evolus' earnings history.

Evolus' stock was trading at $5.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EOLS shares have increased by 83.1% and is now trading at $10.82.
View which stocks have been most impacted by COVID-19.

8 analysts have issued 1 year price objectives for Evolus' stock. Their forecasts range from $7.00 to $25.00. On average, they expect Evolus' share price to reach $16.38 in the next year. This suggests a possible upside of 51.3% from the stock's current price.
View analysts' price targets for Evolus or view top-rated stocks among Wall Street analysts.

1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Evolus include OPKO Health (OPK), Rocket Pharmaceuticals (RCKT), Arcus Biosciences (RCUS), Prothena (PRTA), Zentalis Pharmaceuticals (ZNTL), IGM Biosciences (IGMS), Protagonist Therapeutics (PTGX), Ironwood Pharmaceuticals (IRWD), Cytokinetics (CYTK), Morphic (MORF), Revance Therapeutics (RVNC), Atea Pharmaceuticals (AVIR), Organogenesis (ORGO), Ligand Pharmaceuticals (LGND) and Myovant Sciences (MYOV).
View all of EOLS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), OrganiGram (OGI) and Bionano Genomics (BNGO).

(EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (0.08%) and Vanguard Capital Wealth Advisors (0.02%). Company insiders that own Evolus stock include Lauren P Silvernail and Rui Avelar.
View institutional ownership trends for Evolus.

EOLS stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Capital Wealth Advisors, and Alliancebernstein L.P..
View insider buying and selling activity for Evolus or or view top insider-buying stocks.

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EOLS stock can currently be purchased for approximately $10.82.

Evolus has a market capitalization of $585.58 million and generates $56.54 million in revenue each year. The company earns $-163,010,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis.

Evolus employs 106 workers across the globe.

The official website for Evolus is www.evolus.com.

Evolus is headquartered at 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]